Amantadine treatment of fatigue associated with multiple sclerosis
R. A. Cohen and M. Fisher
Department of Neurology, University of Massachusetts Medical School, Worcester 01655.
Fatigue is a common symptom of multiple sclerosis (MS) that is without an
effective treatment. A double-blind, controlled study of fatigue treatment
was conducted to evaluate the efficacy of amantadine hydrochloride in
treating MS-associated fatigue. Since fatigue cannot be characterized by a
single symptom or behavior, a variety of neuropsychological, behavioral,
and self-report measures were used to monitor changes across different
systems. According to patients' daily diary ratings, amantadine produced
small but statistically significant improvements in fatigue across four of
seven dimensions (overall energy level, concentration, problem solving, and
sense of well-being). In addition, patients with MS who were taking
amantadine performed slightly better on the Stroop Interference Test, an
attentional measure of freedom from distracting information. Although
retrospective reports by patients with MS did not confirm the degree of
improvement recorded on a daily basis, the study's results suggested that
amantadine may offer modest benefits in alleviating the day-to-day
subjective experience of fatigue.
Origin of Fatigue in Multiple Sclerosis: Review of the Literature
Kos et al.
Neurorehabil Neural Repair 2008;22:91-100.
ABSTRACT
A Randomized Controlled Trial of Cognitive Behavior Therapy for Multiple Sclerosis Fatigue
van Kessel et al.
Psychosom. Med. 2008;70:205-213.
ABSTRACT
| FULL TEXT
Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: a randomized, placebo-controlled trial
Lovera et al.
Mult Scler 2007;13:376-385.
ABSTRACT
Amantadine for treatment of fatigue in Guillain-Barre syndrome: a randomised, double blind, placebo controlled, crossover trial
Garssen et al.
J. Neurol. Neurosurg. Psychiatry 2006;77:61-65.
ABSTRACT
| FULL TEXT
Treating fatigue in patients with MS: One step forward, one step back
Schwid and Murray
Neurology 2005;64:1111-1112.
FULL TEXT
Modafinil for fatigue in MS: A randomized placebo-controlled double-blind study
Stankoff et al.
Neurology 2005;64:1139-1143.
ABSTRACT
| FULL TEXT
Apathy: Why Care?
van Reekum et al.
J. Neuropsychiatry Clin. Neurosi. 2005;17:7-19.
ABSTRACT
| FULL TEXT
Fatigue associated with multiple sclerosis: diagnosis, impact and management
Bakshi
Mult Scler 2003;9:219-227.
ABSTRACT
The cognitive performance of patients with multiple sclerosis during periods of high and low fatigue
Parmenter et al.
Mult Scler 2003;9:111-118.
ABSTRACT
Changes in gait and fatigue from morning to afternoon in people with multiple sclerosis
Morris et al.
J. Neurol. Neurosurg. Psychiatry 2002;72:361-365.
ABSTRACT
| FULL TEXT
Efficacy and safety of modafinil (Provigil(R)) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study
Rammohan et al.
J. Neurol. Neurosurg. Psychiatry 2002;72:179-183.
ABSTRACT
| FULL TEXT
Fatigue in multiple sclerosis and its relationship to depression and neurologic disability
Bakshi et al.
Mult Scler 2000;6:181-185.
ABSTRACT
